购物车
您的购物车当前为空
Anticanceragent 233 (compound 5g),一种3,5-双(芳基亚甲基)-4-哌啶酮衍生物,展示出显著的抗癌活性.其对宫颈癌(HeLa)和结肠癌(HCT116)细胞系的GI50值分别仅为0.25及0.23 μM.该化合物中芳基环上的氯原子与20S proteasome催化位点相互作用良好,从而有效地抑制20S proteasome活性,发挥抗癌效果.
Anticanceragent 233 (compound 5g),一种3,5-双(芳基亚甲基)-4-哌啶酮衍生物,展示出显著的抗癌活性.其对宫颈癌(HeLa)和结肠癌(HCT116)细胞系的GI50值分别仅为0.25及0.23 μM.该化合物中芳基环上的氯原子与20S proteasome催化位点相互作用良好,从而有效地抑制20S proteasome活性,发挥抗癌效果.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | 待询 | 待询 | |
| 50 mg | 待询 | 待询 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Anticanceragent 233 (compound 5g) is a 3,5-bis(arylmethyl)-4-piperidone derivative exhibiting anticancer activity, with GI50 values of 0.25 and 0.23 μM against cervical cancer (HeLa) and colon cancer (HCT116) cell lines, respectively. The chloro substituents on the aryl ring of Anticanceragent 233 interact effectively with the catalytic site of the 20S proteasome, inhibiting its activity to deliver its anticancer effects. |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多